“UNSW scientists have developed a proprietary laser activated polysaccharide adhesive system that has been demonstrated in vitro, ex vivo, and in vivo.

One of the main applications of the technology is as a potential replacement for sutures, and as an alternative to albumin solders and other biological glues, alleviating many of their associated disadvantages.



The technology is based on chitosan (deacetylated chitin) obtained form crab shells. The key characteristics of chitosan – the second most frequently used biomaterial after collagen - include non-toxicity, biodegradability, and antimicrobial activity. Applications include: minimal invasive surgery, targeting soft tissues such as nerves, lungs, liver, and bladder; bones and cartilage; and in-situ drug delivery of antibiotics, growth factors, genes, and other therapeutic agents.



NewSouth Innovations is seeking to identify and secure a partner to clinically and commercially develop this proprietary technology. The nature of the investment would be through collaborative research and/or a licence deal”.

Link to NSi Technology Page

External link to Full SMH News article